3 results
Approved WMOCompleted
To determine the toxicity of Zirconium-89 (Zr89) labelled Cetuximab in patient with stage IV cancer.
Approved WMORecruiting
Primary objectiveTo compare the wear rate 60 months after THA of HXLPE stabilized with vitamin E versus conventional UHMWPE for total joint arthroplasty. Secondary objectives- To compare the wear rate at 3,12, 24 and 60 months after THA between…
Approved WMOPending
Primary Objective* To assess the safety, tolerability, and efficacy (in terms of change in DAS28 [using C-ReactiveProtein (CRP)] from baseline) of JNJ-38518168 at a dose of 100 mg/day for up to 12 weekscompared to placebo in subjects with active…